At this year's Society for Minimally-Invasive Technology Meeting in London, there were the expected sessions on stents and visualization issues such as 2-D vs. 3-D imaging. But perhaps the hottest topic was robotic surgery.
At this year's Society for Minimally-Invasive Technology meeting in London, there were the expected sessions on stents and visualization issues such as 2-D vs. 3-D imaging. But perhaps the hottest topic was robotic surgery.
Lonnie Smith, president and CEO of CA-based Intuitive Surgical Inc. says interest in computer-enhanced surgery "is even higher in...
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
